Oncolytics Biotech Inc. (TSE:ONC - Get Free Report) shares were up 24.1% on Tuesday . The company traded as high as C$1.72 and last traded at C$1.70. Approximately 805,450 shares traded hands during mid-day trading, an increase of 496% from the average daily volume of 135,254 shares. The stock had previously closed at C$1.37.
Wall Street Analysts Forecast Growth
Separately, Jones Trading cut Oncolytics Biotech from a "strong-buy" rating to a "hold" rating in a report on Friday, May 16th.
Read Our Latest Analysis on ONC
Oncolytics Biotech Stock Up 24.1%
The firm has a 50 day moving average price of C$0.76 and a two-hundred day moving average price of C$0.93. The company has a quick ratio of 8.86, a current ratio of 2.99 and a debt-to-equity ratio of 11.75. The company has a market capitalization of C$131.03 million, a price-to-earnings ratio of -4.74 and a beta of 1.35.
About Oncolytics Biotech
(
Get Free Report)
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Oncolytics Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.
While Oncolytics Biotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
